Page 1244 - Basic _ Clinical Pharmacology ( PDFDrive )

1230 Index

Norepinephrine transporter (NET), 8t, 95, Odanacatib, 780b rectal suppositories, 564
95b, 96f, 97, 142, 143f Ofatumumab, 970, 992–993 shivering, 563
Norethindrone (acetate), 728t, 729f. Off-labeled uses of drugs, 1153 transdermal fentanyl patch, 564
See also Progestins Ofloxacin, 838 in CNS, 377t
Norethynodrel, 728t. See also Progestins Ogilvie’s syndrome, 1097 constipation caused by, 562
Norfloxacin, 838 Olanzapine contraindications and cautions with, 566
Nortriptyline, 546t Huntington’s disease treated with, 505 dependence, 564–565, 566
Noscapine, 570 psychosis treated with, 515, 520t, 529t drug interactions of, 566t, 566–567,
Notice of Claimed Investigational Exemption structure of, 514f 1169t
for a New Drug (IND), 12f, 15 Olcegepant, 315, 318t. See also Calcitonin endogenous opioid peptides, 554, 554t
Novocain, 460f gene-related peptide mechanism of action in, 557–559
NovoSeven, 623 Oligodendrocytes, 368 cellular actions, 556, 557f
N-Oxidation, 60t Olmesartan hyperalgesia, 559
NPH, 755, 768t. See also Insulin hypertension treated with, 189 receptor distribution and analgesia,
NS3/4A inhibitors, 889–891, 890f on vasoactive peptides, 316t 557f, 557–559, 559f
NS5A inhibitors, 888–889 Olodaterol, 152, 351 receptor types and physiologic effects,
NS5B RNA polymerase inhibitors, 889 Olsalazine, 1107, 1107f 554t, 555t, 556–557
NT79, 317t. See also Neurotensin agonists Omalizumab, 357, 360, 362t, 995 tolerance and dependence, 559, 561t
N-terminal pro-brain natriuretic peptide, Omapatrilat, 310, 317t mixed agonist-antagonist, 553
216 Ombitasvir, 888–889 organ system effects, of morphine and
NT69L, 317t. See also Neurotensin agonists Omecamtiv mecarbil (CK-1827452) surrogates, 559–562
Nucleoside and nucleotide reverse tran- on contractile proteins, 213 CNS, 559–562, 561t
scriptase inhibitors (NRTIs), heart failure treated with, 219–220 peripheral, 560–561
870–876, 871t–872t Omega conotoxin, 370t overdosage, 566
abacavir, 870, 871t Omega-3 essential fatty acids, 337 pharmacodynamics of, 556–562
didanosine, 871t, 874–875 Omega-6 essential fatty acids, 337 pharmacokinetics of, 554–556, 555t
emtricitabine, 871t, 875 Omeprazole, 1091–1095. See also proton- poisoning management for, 1041t, 1045
fundamentals of, 870 pump inhibitors (PPIs) preparations available, 573t
lamivudine, 872t, 875 Omission, errors of, 1149–1150 respiratory depression caused by, 561
in pregnancy, 879t Onchocerciasis, ivermectin for, 941–942 source of, 553
stavudine, 873t, 875 Oncogenes, 949 tolerance, 561t, 564–565
tenofovir, 873t, 875–876 Ondansetron, 292, 297t. See also Serotonin toxicity and undesired effects of, 564t,
zidovudine, 873t, 876 (5-HT) receptor antagonists 564–567
Numeric rating scale (NRS), 562 antiemetic properties of, 1104 Opioid agonists, 567–569, 572t
Nutraceuticals, toxicity of, 3 chemical structure of, 1102f diarrhea treated with, 1100
Nutritional anemias, 594t, 594–595, On-off phenomenon, 497 educating prescribers of, 569b
605t–606t. See also specific types o-Phenylphenol, 899 G io protein-coupled receptor activation
Nutritional rickets, 788 Ophthalmic drugs. See also specific types by, 581, 583f
Nutritional supplements, purified, in elderly mild to moderate
1141–1144 glaucoma, 1064 phenanthrenes, 568, 572t
coenzyme Q10, 1141–1142 macular degeneration, age-related, phenylheptylamines, 568
glucosamine, 1142–1143 1065 phenylpiperidines, 568
melatonin, 1143–1144 Opioid(s), 553–554, 572t. See also Drugs mixed receptor actions
Nystatin, topical, 860 of abuse; specific types benzomorphans, 569
dermatologic, 1073 abuse of, 577t morphinans, 569
addiction, 566 phenanthrenes, 569, 572t
O analgesics, intravenous, 457 preparations available, 573t
o-Benzyl-p-chlorophenol, 899 in breast milk, 1056 strong
Obesity, 289b, 290t case study of, 553, 574 morphinans, 568
Obeticholic acid, 1113–1114 classification and chemistry of, 553–554, phenanthrenes, 567, 572t
Obidoxime, 132 554t phenylheptylamines, 567, 572t
Obiltoxaximab, 995 clinical use of, 563–564 phenylpiperidines, 568, 572t
Obsessive-compulsive disorder, 544 analgesia, 555t, 563 tapentadol, 570, 572t
Occupational toxicology, 1004 anesthesia, 563–564 tramadol, 569–570, 572t
Octopamine, 97f buccal transmucosal, 564 Opioid antagonists, 570–571, 572t, 581
Octreotide, 672f, 673, 683t diarrhea, 563 laxative action of, 1099–1100
diarrhea treated with, 1101 intranasal, 564 preparations available, 573t
variceal hemorrhage treated with, 1114, patient-controlled analgesia, 564 Opioid antitussives, 570, 572t, 573t
1116t pulmonary edema, acute, 563 Opioid-induced hyperalgesia, 559